The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
Insider Insights: Unveiling Takeaways from AACR 2024
Expert Insights on the United States Chemotherapy Shortage
Yale Cancer Center Experts Present New Research on Obesity, Tobacco, Evolution, and Early Onset Cancers at Leading Oncology Conference
CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma